RxDoctor Payments Data

Michael Housley, PA

Physician Assistant · Boise, IDNPI 1043665789

Payments from drug & device makers

$2,328in general payments, 2019–2025

Across 104 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$904
  • Johnson & Johnson$293
  • Galderma Laboratories, L.p.$254
  • UCB, Inc.$187
  • Novartis$157
  • Arcutis Biotherapeutics, Inc.$107
  • plus $427 from 11 others

What the payments were for

  • Food & beverage$2,28098%
  • Education$482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,328 in reported general payments places this provider in the 85th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$104,809
Medicare patients
435
Services billed
2,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib12$85,360
Humira(Cf) PenAdalimumab13$82,610
Dupixent PenDupilumab14$52,304
Clobetasol Propionate118$6,812
Ketoconazole125$1,928
Metronidazole26$1,412
Fluocinonide18$1,259
Triamcinolone Acetonide99$1,229
Minocycline Hcl43$1,200
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip47$988
Doxycycline Hyclate24$638
Spironolactone16$532
Clindamycin Phosphate12$523
Cephalexin24$245
Mupirocin28$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$904$85,36012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →